Description
FOX04-DRI 10mg (Proxofim) – Innovative Senolytic Peptide for Cellular Rejuvenation
Overview
FOX04-DRI (Proxofim) is a groundbreaking research peptide known for its potential in targeting and eliminating senescent cells. By disrupting the interaction between the FOXO4 transcription factor and the p53 tumor suppressor protein, FOX04-DRI may selectively induce apoptosis in aged or damaged cells while preserving healthy ones. This mechanism positions it as a promising candidate in the study of anti-aging, longevity, and tissue regeneration.
Mechanism of Action
FOX04-DRI functions by interfering with FOXO4, a key regulator of cellular aging. Normally, FOXO4 binds to p53, preventing the activation of apoptosis in senescent cells. FOX04-DRI blocks this binding, freeing p53 to trigger programmed cell death in cells that have lost their regenerative capacity. This process, known as senolysis, may contribute to improved tissue function, enhanced recovery, and overall cellular health.
Potential Research Applications
- Longevity Studies: Investigating the role of FOX04-DRI in delaying aging by clearing senescent cells.
- Cellular Rejuvenation: Exploring its effects on tissue regeneration and repair.
- Neurodegenerative Research: Studying its impact on age-related cognitive decline and neuroinflammation.
- Oncology Research: Assessing its potential in modulating tumor environments by targeting senescent cells.
Key Features
- Targets and removes senescent cells via a p53-dependent mechanism.
- May support healthy aging and tissue repair.
- Available in a 10mg lyophilized vial for research use.
